AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11238232 — intervention group
Group type: EXPERIMENTAL
Intervention: Two full vaccine doses
Number of subjects: 0
Study 11238232 — intervention group
Group type: COMPARATOR
Intervention: One-third of a full dose of CFA-ETEC bacteria
Number of subjects: 0
Study 9840528 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver embolization with gel foam powder
Number of subjects: 41
Study 7517169 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate
Number of subjects: 0
Study 7517169 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (control)
Number of subjects: 0
Study 2543304 — intervention group
Group type: EXPERIMENTAL
Intervention: COMP (cyclophosphamide, vincristine, methotrexate, procarbazine)
Number of subjects: 181
Study 2543304 — intervention group
Group type: EXPERIMENTAL
Intervention: COMP-VAN (cyclophosphamide, vincristine, methotrexate, procarbazine and etoposide, adriamycin, nimustine)
Number of subjects: 181
Study 2543304 — intervention group
Group type: EXPERIMENTAL
Intervention: CAV-PVP hybrid regimen (cyclophosphamide, adriamycin, vincristine and cisplatin, etoposide)
Number of subjects: 181
Study 2543304 — intervention group
Group type: COMPARATOR
Intervention: CT alone
Number of subjects: 181
Study 2543304 — intervention group
Group type: EXPERIMENTAL
Intervention: CT plus chest RT (40 Gy)
Number of subjects: 181
Study 2543304 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 181
Study 2543304 — intervention group
Group type: COMPARATOR
Intervention: Not receiving PCI
Number of subjects: 181
Study 4826316 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 kg back load
Number of subjects: 8
Study 4826316 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 kg handcart
Number of subjects: 8
Study 4826316 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 kg handcart
Number of subjects: 8
Study 4826316 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 kg handcart
Number of subjects: 8
Study 30536797 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole oral suspension formulations
Number of subjects: 0
Study 30536797 — intervention group
Group type: COMPARATOR
Intervention: Reference product of posaconazole oral suspension
Number of subjects: 0
Study 28942444 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-mediated dilation (FMD) measured in angina patients (n = 128)
Number of subjects: 194
Study 28942444 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary flow velocity reserve (CFVR) assessed in angina patients (n = 128)
Number of subjects: 194
Study 28942444 — intervention group
Group type: COMPARATOR
Intervention: Coronary flow velocity reserve (CFVR) assessed in reference population (n = 21)
Number of subjects: 194
Study 26001337 — intervention group
Group type: EXPERIMENTAL
Intervention: Relamorelin (100 μg/d, given subcutaneously)
Number of subjects: 48
Study 26001337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 22977278 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventionists with >10 Wingspan cases submitted for credentialing
Number of subjects: 213
Study 22977278 — intervention group
Group type: COMPARATOR
Intervention: Sites enrolling <12 patients
Number of subjects: 213
Study 22977278 — intervention group
Group type: COMPARATOR
Intervention: Interventionists with less Wingspan experience
Number of subjects: 213
Study 22977278 — intervention group
Group type: COMPARATOR
Intervention: Low enrollment sites
Number of subjects: 213
Study 21557836 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine N-butyl bromide (HBB)
Number of subjects: 140
Study 21557836 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin
Number of subjects: 140
Study 21557836 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 140
Study 21557836 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 140
Study 18773845 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminobisphosphonates as preventive treatment at the time of diagnosis of bone metastatic prostate cancer
Number of subjects: 0
Study 18773845 — intervention group
Group type: COMPARATOR
Intervention: Local treatments (external beam radiotherapy, bone surgery) and systemic treatments (androgen deprivation, chemotherapy)
Number of subjects: 0
Study 16139812 — intervention group
Group type: EXPERIMENTAL
Intervention: Phobogenic stimuli (spiders)
Number of subjects: 0
Study 16139812 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (neutral stimuli - mushrooms)
Number of subjects: 0
Study 12709725 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg subcutaneous etanercept twice weekly for 24 weeks
Number of subjects: 182
Study 12709725 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg subcutaneous etanercept twice weekly for 24 weeks
Number of subjects: 182
Study 12709725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 10932442 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated mental health and substance use treatment program
Number of subjects: 0
Study 10932442 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital treatment
Number of subjects: 0
Study 8981131 — intervention group
Group type: EXPERIMENTAL
Intervention: dl-norgestrel (2 mg) with ethinyl oestradiol (200 micrograms)
Number of subjects: 540
Study 8981131 — intervention group
Group type: COMPARATOR
Intervention: levonorgestrel (1 mg) with ethinyl oestradiol (200 micrograms)
Number of subjects: 540
Study 1428162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone for 3 days
Number of subjects: 157
Study 1428162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin/sulphadiazine for 3 days
Number of subjects: 157
Study 1428162 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 157
Study 1428162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone vs Ampicillin/sulphadiazine
Number of subjects: 157
Study 3908726 — intervention group
Group type: EXPERIMENTAL
Intervention: S6472 (750 mg b.i.d.)
Number of subjects: 250
Study 3908726 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor (CCL) (750 mg t.i.d.)
Number of subjects: 250
Study 3908726 — intervention group
Group type: EXPERIMENTAL
Intervention: S6472
Number of subjects: 250
Study 3908726 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor (CCL)
Number of subjects: 250
Study 30759761 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation (TR)
Number of subjects: 136
Study 30759761 — intervention group
Group type: COMPARATOR
Intervention: Conventional Rehabilitation (CR)
Number of subjects: 136
Study 29720378 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at PC5
Number of subjects: 31
Study 29720378 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at LU5
Number of subjects: 31
Study 27455316 — intervention group
Group type: EXPERIMENTAL
Intervention: Montmorency tart cherry concentrate (MC) supplementation (30 mL twice per day for 8 days)
Number of subjects: 16
Study 27455316 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) supplementation
Number of subjects: 16
Study 27455316 — intervention group
Group type: EXPERIMENTAL
Intervention: Montmorency tart cherry concentrate (MC) supplementation
Number of subjects: 16
Study 25424425 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-of-care plus mobile phone-based SMS intervention for 6 months
Number of subjects: 216
Study 25424425 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 216
Study 21832285 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (irinotecan with either bolus or infused 5-fluorouracil)
Number of subjects: 567
Study 19200959 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 IU hCG
Number of subjects: 305
Study 19200959 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg GnRHa (buserelin) supplemented with 1,500 IU hCG
Number of subjects: 305
Study 17587713 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of acetylcholine
Number of subjects: 199
Study 17587713 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-CRP
Number of subjects: 199
Study 17587713 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-CRP > or = 2 mg/L
Number of subjects: 199
Study 15756035 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐HPR (fenretinide)
Number of subjects: 48
Study 15756035 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study 12871005 — intervention group
Group type: EXPERIMENTAL
Intervention: Show group (LA syringe shown to child)
Number of subjects: 25
Study 12871005 — intervention group
Group type: COMPARATOR
Intervention: No-show group (LA syringe concealed from child)
Number of subjects: 25
Study 9525542 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin anticoagulation
Number of subjects: 6797
Study 7640431 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose triacetate (CTA)
Number of subjects: 31
Study 7640431 — intervention group
Group type: COMPARATOR
Intervention: Polysulphon (PS)
Number of subjects: 31
Study 2533802 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.5 g/kg) plus diazepam (5 mg)
Number of subjects: 16
Study 2533802 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.5 g/kg) plus meclophenoxate (100 mg)
Number of subjects: 16
Study 2533802 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.5 g/kg) plus placebo
Number of subjects: 16
Study 2533802 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus placebo
Number of subjects: 16
Study 2533802 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.5 g/kg)
Number of subjects: 16
Study 568172 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein hydrolysate
Number of subjects: 25
Study 568172 — intervention group
Group type: COMPARATOR
Intervention: Soy-based formulas
Number of subjects: 25
Study 568172 — intervention group
Group type: COMPARATOR
Intervention: Milk-based formulas
Number of subjects: 25
Study 31054159 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (400 iU daily) drops
Number of subjects: 195
Study 31054159 — intervention group
Group type: COMPARATOR
Intervention: Placebo drops (coconut and palm kernel oil)
Number of subjects: 195
Study 31054159 — intervention group
Group type: EXPERIMENTAL
Intervention: UV light exposure (measured in a nonrandomized subset)
Number of subjects: 195
Study 31424481 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel-Aspirin
Number of subjects: 10051
Study 31424481 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 10051
Study 29390278 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational activities in the classroom
Number of subjects: 18
Study 29390278 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in the school environment (nudge strategies)
Number of subjects: 18
Study 29390278 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational activities and changes in the school environment
Number of subjects: 18
Study 29390278 — intervention group
Group type: COMPARATOR
Intervention: Control group (without any activity)
Number of subjects: 18
Study 25948166 — intervention group
Group type: EXPERIMENTAL
Intervention: OSTAP block with 20 ml 0.25% bupivacaine
Number of subjects: 76
Study 25948166 — intervention group
Group type: COMPARATOR
Intervention: Control group (paracetamol, tenoxicam, and tramadol as required)
Number of subjects: 76
Study 23541971 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 813
Study 23541971 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CRT)
Number of subjects: 813
Study 20519697 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg day(-1) orally for 4 weeks)
Number of subjects: 379
Study 20519697 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg day(-1) orally for 4 weeks)
Number of subjects: 379
Study 19333536 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg)
Number of subjects: 80
Study 19333536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 16677152 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic (99m)Tc-HIDA SPECT
Number of subjects: 18
Study 15186687 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal risk procedures
Number of subjects: 0
Study 15186687 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical measures
Number of subjects: 0
Study 11590500 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IL-2 (1.2 million IU/m2 once daily) in conjunction with HAART
Number of subjects: 115
Study 11590500 — intervention group
Group type: COMPARATOR
Intervention: HAART alone (control group)
Number of subjects: 115
Study 9547441 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 2.5 mg
Number of subjects: 0
Study 9547441 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5.0 mg
Number of subjects: 0
Study 9547441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8147960 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified insulin treatment
Number of subjects: 102
Study 8147960 — intervention group
Group type: COMPARATOR
Intervention: Standard insulin treatment
Number of subjects: 102
Study 2897299 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (240 mg)
Number of subjects: 6
Study 2897299 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (200 mg)
Number of subjects: 6
Study 2897299 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (100 mg)
Number of subjects: 6
Study 2897299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30883331 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 42
Study 30883331 — intervention group
Group type: COMPARATOR
Intervention: Dry needling
Number of subjects: 42
Study 29976553 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus beetroot juice (4.2 mmol concentrated beetroot juice)
Number of subjects: 24
Study 29976553 — intervention group
Group type: COMPARATOR
Intervention: Exercise plus placebo
Number of subjects: 24
Study 26707134 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 μg/day calcitriol (n=48)
Number of subjects: 98
Study 26707134 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=50)
Number of subjects: 98
Study 25111032 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory-based cognitive training for 8 weeks
Number of subjects: 0
Study 25111032 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up testing 6 months after training
Number of subjects: 0
Study 22261439 — intervention group
Group type: EXPERIMENTAL
Intervention: B vitamin supplementation (B6, B12, folic acid) for 6 weeks
Number of subjects: 36
Study 22261439 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (aerobic and strength training) for 6 weeks
Number of subjects: 36
Study 22261439 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of B vitamin supplementation and exercise training for 6 weeks
Number of subjects: 36
Study 22261439 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 36
Study 20437565 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (1,200mg/day)
Number of subjects: 10
Study 20437565 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (40 mg/day)
Number of subjects: 10
Study 17510229 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching of quadriceps
Number of subjects: 39
Study 17510229 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching of hamstring
Number of subjects: 39
Study 17510229 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching of adductors
Number of subjects: 39
Study 16079656 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-layer closure with simple interrupted 6-0 polypropylene sutures
Number of subjects: 65
Study 16079656 — intervention group
Group type: COMPARATOR
Intervention: Double-layer closure with simple interrupted 6-0 polypropylene plus inverted deep dermal 5-0 polyglactin sutures
Number of subjects: 65
Study 12385921 — intervention group
Group type: EXPERIMENTAL
Intervention: Saw palmetto herbal blend (SPHB)
Number of subjects: 40
Study 12385921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10630348 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural therapy (injection of local anesthetic without adrenaline into specific trigger points)
Number of subjects: 61
Study 8520623 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethindrone (low-dose therapy)
Number of subjects: 0
Study 2239806 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone 12 mg/m2 daily for 3 days plus etoposide 100 mg/m2 daily by constant infusion for 5 days
Number of subjects: 32
Study 2239806 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone 12 mg/m2 daily for 3 days plus etoposide 150 mg/m2 daily by constant infusion for 5 days
Number of subjects: 32
Study 2239806 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone 12 mg/m2 daily for 3 days plus etoposide 200 mg/m2 daily by constant infusion for 5 days
Number of subjects: 32
Study 2239806 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone plus etoposide (various doses)
Number of subjects: 32
Study 374202 — intervention group
Group type: EXPERIMENTAL
Intervention: etamsylate
Number of subjects: 107
Study 374202 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 107
Study 29962254 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble mate tea (SMT)
Number of subjects: 9
Study 29962254 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 9
Study 28303900 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine (20 mg)
Number of subjects: 63
Study 28303900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 28303900 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI assessment during inhibition task
Number of subjects: 63
Study 26235968 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 mg/day) for 6 months
Number of subjects: 90
Study 26235968 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (25 mg daily) for 6 months
Number of subjects: 90
Study 26235968 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vitamin E and clomiphene citrate for 6 months
Number of subjects: 90
Study 23518604 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (12-week course)
Number of subjects: 0
Study 23518604 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity exercise group
Number of subjects: 0
Study 23518604 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise group
Number of subjects: 0
Study 23518604 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intensity
Number of subjects: 0
Study 23518604 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intensity (after adjustment for confounders)
Number of subjects: 0
Study 21877679 — intervention group
Group type: EXPERIMENTAL
Intervention: ReSTOR +3.00-D add IOL
Number of subjects: 40
Study 21877679 — intervention group
Group type: COMPARATOR
Intervention: ReSTOR +4.00-D add IOL
Number of subjects: 40
Study 21877679 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 19728188 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone
Number of subjects: 0
Study 19728188 — intervention group
Group type: COMPARATOR
Intervention: Existing method
Number of subjects: 0
Study 16899099 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% CHX mouthrinse
Number of subjects: 90
Study 16899099 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% CHX/0.055% sodium fluoride mouthrinse
Number of subjects: 90
Study 16899099 — intervention group
Group type: COMPARATOR
Intervention: Positive control (CHX mouthrinse)
Number of subjects: 90
Study 16899099 — intervention group
Group type: COMPARATOR
Intervention: Negative control (placebo)
Number of subjects: 90
Study 15313956 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 12562
Study 15313956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12562
Study 11558245 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine medical testing (12-lead electrocardiogram, complete blood count, serum glucose measurements)
Number of subjects: 1025
Study 11558245 — intervention group
Group type: COMPARATOR
Intervention: Selective medical testing (no routine tests unless new or worsening medical problems)
Number of subjects: 1025
Study 9756146 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal apomorphine
Number of subjects: 9
Study 9756146 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 9
Study 7834052 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal blood circulation and oxygenation during bypass surgery
Number of subjects: 0
Study 7834052 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion of the myocardium following removal of the aortic cross clamp
Number of subjects: 0
Study 3139285 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day rIL-2 bolus (10^5 units/kg every 8 hours) followed by LAK cell infusion
Number of subjects: 15
Study 3139285 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day rIL-2 prime and 6-day continuous infusion rIL-2 (3 x 10^6 units/m2/day) with LAK cell infusion
Number of subjects: 15
Study 3139285 — intervention group
Group type: EXPERIMENTAL
Intervention: LAK cell infusion
Number of subjects: 15
Study 3139285 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro LAK generation cultures
Number of subjects: 15
Study 29532729 — intervention group
Group type: EXPERIMENTAL
Intervention: Endolymphatic sac shunt insertion
Number of subjects: 29
Study 29532729 — intervention group
Group type: COMPARATOR
Intervention: Ventilating tube insertion in tympanic membrane
Number of subjects: 29
Study 26910333 — intervention group
Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP)
Number of subjects: 1131
Study 26910333 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I (hs-cTnI)
Number of subjects: 1131
Study 26195509 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir plus pegylated interferon alpha/ribavirin (PR)
Number of subjects: 3124
Study 26195509 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus pegylated interferon alpha/ribavirin (PR)
Number of subjects: 3124